Ocrelizumab biosimilar (Amgen)
- Generic Name
- Ocrelizumab biosimilar (Amgen)
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
Phase 3
Recruiting
- Conditions
- Relapsing-remitting Multiple Sclerosis (RRMS)
- Interventions
- First Posted Date
- 2024-11-22
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 444
- Registration Number
- NCT06700343
- Locations
- 🇺🇸
Profound Research - Neurology Center of Southern California, Carlsbad, California, United States
🇺🇸Mountain Neurological Research Center, Basalt, Colorado, United States
🇺🇸Advanced Neurosciences Research, Llc, Fort Collins, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath